Benzinga's Top #PreMarket Gainers

shares rose 21.21 percent to $1.200 after the company reported that the U.S. FDA has granted Orphan Drug Designation to Pluristem's PLX-PAD cells.

shares rose 12.61 percent to $1.25. Roth initiated coverage on PBMD with a Buy rating and a $6 price target.

shares rose 7.90 percent to $9.01. Steven Cohen reported a 5.3 percent stake in Chimerix.

shares rose 4.07 percent to $3.84 in pre-market trading after the company raised its Q4 forecast.

shares rose 1.77 percent to $32.69 in pre-market trading after falling 0.86 percent on Wednesday.